GAIN THERAPEUTICS, INC Interest Income (Expense), Net
GAIN THERAPEUTICS, INC (GANX) reported Interest Income (Expense), Net of $105.41 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNet · last filed 2024-11-14
- GAIN THERAPEUTICS, INC interest income (expense), net for the quarter ending 2024-09-30 was $105.41K, a 0.56% decline year-over-year.
- GAIN THERAPEUTICS, INC interest income (expense), net for the quarter ending 2024-06-30 was $84.53K, a 34.94% decline year-over-year.
- GAIN THERAPEUTICS, INC interest income (expense), net for the quarter ending 2024-03-31 was $115.30K, a 24.16% decline year-over-year.
- GAIN THERAPEUTICS, INC interest income (expense), net for the quarter ending 2023-12-31 was $106.27K, a 35.11% decline year-over-year.
- GAIN THERAPEUTICS, INC interest income (expense), net for fiscal 2023 was $494.23K, a 31.67% increase from fiscal 2022.
- GAIN THERAPEUTICS, INC interest income (expense), net for fiscal 2022 was $375.36K, a 2904.06% increase from fiscal 2021.
- GAIN THERAPEUTICS, INC interest income (expense), net for fiscal 2021 was $12.49K, a 243.55% increase from fiscal 2020.
- GAIN THERAPEUTICS, INC interest income (expense), net for fiscal 2020 was $3.64K.
| Period end | Interest Income (Expense), Net 3 month | Interest Income (Expense), Net 6 month | Interest Income (Expense), Net 9 month | Interest Income (Expense), Net 12 month |
|---|---|---|---|---|
| 2024-09-30 | $105.41K 10-Q · filed 2024-11-14 | $189.94K derived: sum of 2 quarters · filed 2024-11-14 | $305.24K 10-Q · filed 2024-11-14 | $411.51K derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | $84.53K 10-Q · filed 2024-08-08 | $199.83K 10-Q · filed 2024-08-08 | $306.10K derived: sum of 3 quarters · filed 2024-08-08 | $412.10K derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-03-31 | $115.30K 10-Q · filed 2024-05-14 | $221.57K derived: sum of 2 quarters · filed 2024-05-14 | $327.57K derived: sum of 3 quarters · filed 2024-11-14 | $457.50K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-12-31 | $106.27K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $212.27K derived: sum of 2 quarters · filed 2024-11-14 | $342.20K derived: sum of 3 quarters · filed 2024-11-14 | $494.23K 10-K · filed 2024-03-26 |
| 2023-09-30 | $106.00K 10-Q · filed 2024-11-14 | $235.93K derived: sum of 2 quarters · filed 2024-11-14 | $387.96K 10-Q · filed 2024-11-14 | $551.74K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $129.93K 10-Q · filed 2024-08-08 | $281.96K 10-Q · filed 2024-08-08 | $445.74K derived: sum of 3 quarters · filed 2024-08-08 | $599.07K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $152.03K 10-Q · filed 2024-05-14 | $315.81K derived: sum of 2 quarters · filed 2024-05-14 | $469.14K derived: sum of 3 quarters · filed 2024-05-14 | $529.04K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $163.78K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $317.11K derived: sum of 2 quarters · filed 2024-03-26 | $377.01K derived: sum of 3 quarters · filed 2024-03-26 | $375.36K 10-K · filed 2024-03-26 |
| 2022-09-30 | $153.33K 10-Q · filed 2023-11-14 | $213.23K derived: sum of 2 quarters · filed 2023-11-14 | $211.58K 10-Q · filed 2023-11-14 | $211.85K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $59.90K 10-Q · filed 2023-08-10 | $58.25K 10-Q · filed 2023-08-10 | $58.52K derived: sum of 3 quarters · filed 2023-08-10 | $63.43K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$1.65K 10-Q · filed 2023-05-12 | -$1.38K derived: sum of 2 quarters · filed 2023-05-12 | $3.53K derived: sum of 3 quarters · filed 2023-05-12 | $9.44K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $267.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $5.18K derived: sum of 2 quarters · filed 2023-03-23 | $11.09K derived: sum of 3 quarters · filed 2023-03-23 | $12.49K 10-K · filed 2023-03-23 |
| 2021-09-30 | $4.92K 10-Q · filed 2022-11-10 | $10.82K derived: sum of 2 quarters · filed 2022-11-10 | $12.23K 10-Q · filed 2022-11-10 | $19.12K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $5.90K 10-Q · filed 2022-08-08 | $7.31K 10-Q · filed 2022-08-08 | $14.20K derived: sum of 3 quarters · filed 2022-08-08 | $14.21K derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $1.41K 10-Q · filed 2022-05-16 | $8.30K derived: sum of 2 quarters · filed 2022-05-16 | $8.31K derived: sum of 3 quarters · filed 2022-05-16 | $6.79K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $6.89K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $6.90K derived: sum of 2 quarters · filed 2022-03-25 | $5.38K derived: sum of 3 quarters · filed 2022-03-25 | $3.64K 10-K · filed 2022-03-25 |
| 2020-09-30 | $7.00 10-Q · filed 2021-11-12 | -$1.51K derived: sum of 2 quarters · filed 2021-11-12 | -$3.26K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$1.52K 10-Q · filed 2021-08-12 | -$3.27K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$1.75K 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |